November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 20, 2024

EBV: The Virus Behind Multiple Autoimmune Diseases

EBV infects >95% of adults globally, yet only triggers autoimmunity in some - researchers identified several key mechanisms, including autoimmune-promoting EBV strains and genetic variants, that may explain why certain individuals develop diseases like lupus, MS, and rheumatoid arthritis.

Conexiant

November 19, 2024

Spinal Cord Stimulation Effective for Chronic Pain

Conexiant

November 19, 2024

Predicting ICH Causes: MRI Advantage

Conexiant

November 19, 2024

Gantenerumab Linked to ARIA Risk in Early Alzheimer's Disease

86% of ARIA-E cases occurred within the first 64 weeks of gantenerumab treatment, with APOE ε4 homozygotes showing nearly 5-fold increased risk.

Conexiant

November 19, 2024

Analysis Maps Broad Semaglutide Eligibility

An estimated 136.8 million U.S. adults are eligible for semaglutide, a number exceeding current eligibility for statins, according to an analysis.

Conexiant

November 19, 2024

Novel Stroke Drug Shows 12-Hour Window

Despite a median treatment time of 9.5 hours after stroke onset - more than twice the current therapeutic window - JX10 showed significantly better functional outcomes than placebo with no symptomatic intracranial hemorrhage events.

Conexiant

November 19, 2024

Does Earlier TDF Reduce HBV Transmission?

Conexiant